Mechanisms of asthma and allergic inflammationSputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis
Section snippets
Subjects
Patients with eosinophilic bronchitis, patients with asthma, and healthy volunteers were recruited from respiratory clinics and from staff at Glenfield Hospital. Subjects with asthma (n = 30) gave a suggestive history and had objective evidence of variable airflow obstruction as indicated by one or more of the following: (1) methacholine airway hyperresponsiveness (PC20 FEV1 < 8 mg/mL), (2) >15% improvement in FEV1 10 minutes after 200 μg inhaled salbutamol, or (3) peak expiratory flow (>20%
Results
The mucolytic dithiothreitol affected recovery of IL-13 by using both commercial ELISA kits (Caltag-Medsystems and R&D). The percentage recovery (coefficient of variation) of standards spiked with dithiothreitol compared with standards without dithiothreitol was similar with both assays: 38% (14%) and 36% (29%) for the Caltag-Medsystems and R&D ELISA, respectively. The Caltag-Medsytems ELISA was more sensitive and therefore was further validated. The recovery of IL-13 standard after dialysis
Discussion
This is the first study to fully validate the measurement of IL-13 in induced sputum. In addition, this study has made two important and novel observations. First, we have shown that the expression of IL-13 protein in the bronchial submucosa and the sputum concentration of IL-13 were increased in asthma compared with eosinophilic bronchitis, supporting the concept that IL-13 plays a critical role in the pathophysiology of asthma. Second, we identified that most of the cells in the bronchial
References (22)
- et al.
TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis
J Allergy Clin Immunol
(2002) - et al.
Chronic cough resembles asthma with IL-5 and granulocyte-macrophage colony-stimulating factor gene expression in bronchoalveolar cells
J Allergy Clin Immunol
(1998) - et al.
Measurement of eotaxin (CCL11) in induced sputum supernatants: validation and detection in asthma
J Allergy Clin Immunol
(2004) - et al.
Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma
J Allergy Clin Immunol
(1997) - et al.
Eosinophils in asthma and other allergic diseases
Br Med Bull
(2000) Th-2 cytokines in allergic disease
Br Med Bull
(2000)- et al.
Mast-cell infiltration of airway smooth muscle in asthma
N Engl J Med
(2002) - et al.
Comparison of airway immunopathology of eosinophilic bronchitis and asthma
Thorax
(2003) - et al.
Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma
Clin Exp Allergy
(2003) - et al.
Histamine and methacholine inhalation tests: a laboratory tidal breathing protocol
(1994)
The use of induced sputum to investigate airway inflammation
Thorax
Cited by (149)
Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice
2023, Journal of Allergy and Clinical ImmunologyWAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation — Updates in COVID-19
2021, World Allergy Organization JournalCitation Excerpt :Patients with NAEB have increased mast cells in bronchial brushings, whereas asthmatics have increased mast cells in airway smooth muscle cells, a finding reported to be inversely related to airway hyperresponsiveness in asthma.84,134 In addition, patients with NAEB have decreased IL-13 in bronchial submucosa and sputum135 and less narrowing of the airway lumen compared to asthma, although both asthma and NAEB express airway remodeling.136 Unlike asthma, there is marked expression of the endogenous bronchodilator PGE-2134,137 in NAEB, which may account for preservation of deep inspiration-induced bronchoprotective effect from cough,113,134 and an antiproliferative effect of bronchial smooth muscle.84
A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers
2018, Drug Metabolism and PharmacokineticsCitation Excerpt :However, NCT00638989 only included males [25], which could have potentially affected the body weight distribution of the non-Japanese population due to the inherent correlation of sex and body weight. Another potential limitation of our study is that it was carried out in healthy volunteers, who do not display elevated concentrations of IL-13 [35,36]. However, previous studies have demonstrated that tralokinumab has a similar PK profile in patients with asthma [25] and healthy volunteers [27], suggesting that there is no evidence of target-mediated drug disposition for tralokinumab, in line with the linear PK observed across the dose range investigated in this study.
Cough and Eosinophilia
2019, Journal of Allergy and Clinical Immunology: In PracticeDifferent expression levels of interleukin-36 in asthma phenotypes
2024, Allergy, Asthma and Clinical Immunology
Supported by a grant from Asthma UK and Cambridge Antibody Technology. Dr Brightling is supported by a DoH Clinician Scientist Award.